The approach of inducing a DUOX1 and NOX2-mediated immune response in uterine cervical mucosa is clinically expected to reinforce immune response to HPV infection and thus increase the survival of cervical cancer patients. The gene discussed is CYBB; the disease is cervical carcinoma.